Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H35NO4 |
Molecular Weight | 413.5497 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12OC3=C4C(C[C@H]5NCC[C@@]14[C@@]56CC[C@@]2(OC)[C@]([H])(C6)[C@](C)(O)C(C)(C)C)=CC=C3O
InChI
InChIKey=YOYLLRBMGQRFTN-IOMBULRVSA-N
InChI=1S/C25H35NO4/c1-21(2,3)22(4,28)16-13-23-8-9-25(16,29-5)20-24(23)10-11-26-17(23)12-14-6-7-15(27)19(30-20)18(14)24/h6-7,16-17,20,26-28H,8-13H2,1-5H3/t16-,17-,20-,22+,23-,24+,25-/m1/s1
Norbuprenorphine is a major metabolite of buprenorphine and potent agonist of μ, δ, and κ opioid receptors. Norbuprenorphine is the only known active metabolite of buprenorphine. It has been shown to be a respiratory depressant in rats, but only at concentrations at least 50-fold greater than those observed following application to humans of BuTrans 20 mcg/h. Compared with buprenorphine, norbuprenorphine causes minimal antinociception but greater respiratory depression. In rats, nor-buprenorphine had 1/50th the analgesic potency of buprenor-phine but 10-fold greater respiratory depressant potency. Norbuprenorphine is an in vitro substrate of the efflux transporter P-glycoprotein (Mdr1). Norbuprenorphine is an in vitro and in vivo substrate of P-glycoprotein. P-glycoprotein-mediated efflux influences brain access and antinociceptive, but not the respiratory, effects of norbuprenorphine.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17455115
Curator's Comment: Norbuprenorphine contributes to the central effects seen after chronic BUP administration as this study demonstrated its entry into the sheep brain.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17455115
Sheep were administered 0.6 mg kg(-1) Norbuprenorphine as 4-min i.v. infusions.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12756210
Compared with buprenorphine, norbuprenorphine demonstrated a lower inhibitory potency with CYP2D6(22.4% inhibition at 20uM norbuprenorphine) and CYP3A4 (13.6%inhibition at 20uM) in microsomes from human cDNA-expressing lymphoblast cells.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Norbuprenorphine
Created by
admin on Sat Dec 16 02:04:04 GMT 2023 , Edited by admin on Sat Dec 16 02:04:04 GMT 2023
|
PRIMARY | |||
|
78715-23-8
Created by
admin on Sat Dec 16 02:04:04 GMT 2023 , Edited by admin on Sat Dec 16 02:04:04 GMT 2023
|
PRIMARY | |||
|
DTXSID60891436
Created by
admin on Sat Dec 16 02:04:04 GMT 2023 , Edited by admin on Sat Dec 16 02:04:04 GMT 2023
|
PRIMARY | |||
|
C043585
Created by
admin on Sat Dec 16 02:04:04 GMT 2023 , Edited by admin on Sat Dec 16 02:04:04 GMT 2023
|
PRIMARY | |||
|
114976
Created by
admin on Sat Dec 16 02:04:04 GMT 2023 , Edited by admin on Sat Dec 16 02:04:04 GMT 2023
|
PRIMARY | |||
|
100000175315
Created by
admin on Sat Dec 16 02:04:04 GMT 2023 , Edited by admin on Sat Dec 16 02:04:04 GMT 2023
|
PRIMARY | |||
|
7E53B4O073
Created by
admin on Sat Dec 16 02:04:04 GMT 2023 , Edited by admin on Sat Dec 16 02:04:04 GMT 2023
|
PRIMARY |
PARENT (METABOLITE ACTIVE)
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD